ClinicalTrials.gg
RecruitingNCT07359638Updated May 1, 2026

Impact of a Mandibular Oral Repositioning Device on Sleep Quality, Heart Rate Variability, & SpO2

An interventional study of Mandibular Oral Repositioning Appliance in Sleep, sponsored by University of Calgary. Recruiting at 1 site in Canada. Open to participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University of Calgary · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies in Sleep Initiation and Maintenance Disorders with a site in Canada — 21 open to participants now, 26 under way, 1 of them phase 3. Sleep Initiation and Maintenance Disorders · Canada.

Planned enrollment
78th of 96
24 · median 89
Started
2026
with 1 other
No phase
56 of 104
13 open now
Primary completion
2026-08
later than 10 of 25 live
Registered
103rd of 104
by date
Lead sponsor
7 of 104
University of Calgary

Among the 104 studies in Sleep Initiation and Maintenance Disorders with a site in Canada, this one is the 78th largest by planned enrollment of the 96 interventional ones that give a count, is one of 2 that started in 2026, is one of 56 with no phase, reaches primary completion later than 10 of the 25 other live ones, and was the 103rd registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

21 of the 104 studies in Sleep Initiation and Maintenance Disorders with a site in Canada are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 40 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Sleep Initiation and Maintenance Disorders with a site in Canada, or all of them as a file.
02

Study summary

Fatigue, poor sleep quality, and reduced physiological recovery are common even among otherwise healthy adults. Subtle factors such as jaw position during sleep and breathing efficiency may contribute to these issues. The mandible (lower jaw) is suspended by muscles and ligaments rather than fixed joints, making it susceptible to small positional changes during sleep. Even mild misalignment of the lower jaw can reduce airway space, alter breathing mechanics, and disrupt sleep architecture, which may in turn affect autonomic regulation and recovery.

This study will evaluate whether a custom mandibular oral repositioning appliance (px3™) improves sleep quality and recovery-related physiological measures compared with a placebo oral device. The px3™ device gently advances the lower jaw during sleep, which may help maintain airway openness and support more stable breathing. The placebo device is custom-fitted but holds the jaw in a neutral position without mandibular advancement, allowing for controlled comparison of device effects.

Using a randomized crossover design, each participant will wear both the px3™ device and the placebo device during separate intervention phases, allowing participants to serve as their own control. The study will take place over approximately 12 weeks and includes baseline monitoring without any oral appliance, two intervention phases, a washout period between conditions, and a short follow-up period.

Participants will undergo non-invasive digital dental scans to fabricate two custom oral devices. Sleep, heart rate variability (HRV), and blood oxygen saturation (SpO₂) will be continuously monitored using a wrist-worn wearable device throughout the study, except during bathing or charging. Participants will also complete brief questionnaires and sleep logs to report comfort, adherence, perceived effects, and factors that may influence sleep (e.g., illness, travel, or alcohol use).

The primary outcomes of interest are changes in sleep stage distribution (including deep, light, and REM sleep), HRV, and SpO₂ when using the PX3™ device compared with the placebo device. Secondary outcomes include participant comfort, adherence, and user experience. The findings from this study will help determine whether mandibular oral repositioning may support sleep quality and physiological recovery in healthy adults.

Read the detailed description
  1. Background and Rationale

    Fatigue, stress, and burnout are increasingly prevalent among healthy, high-performance individuals. Two often-overlooked contributors are jaw misalignment (malocclusion) and over-breathing, both of which can impair respiratory efficiency, sleep quality, and physiological recovery.

    The mandible is unique in the human body, suspended by muscles and ligaments rather than fixed joints. This provides a wide range of motion but makes it susceptible to misalignment during activity or sleep. Even mild malocclusion can compromise airway patency, neuromuscular coordination, and craniofacial balance. Consequences may include reduced respiratory efficiency, increased fatigue, impaired concentration, and elevated injury risk. Secondary issues from mouth-breathing and over-breathing - such as poor oxygen-carbon dioxide balance and disrupted sleep - further contribute to fatigue and suboptimal performance.

    The PX3™ Mandibular Oral Repositioning Appliance is designed to advance and stabilize the lower jaw, optimizing airway openness and physiological efficiency. The device functions similarly to the airway-opening maneuver used in cardiopulmonary resuscitation, slightly bringing the mandible forward to facilitate airflow. Each PX3™ appliance is custom-fitted to align and lock opposing teeth, stabilizing the jaw during sleep or high-stress activities.

    PX3™ designs are based on three physical principles:

    (i) Poiseuille's Law: Increasing airway volume increases oxygen intake. (ii) Gas Exchange Law: Optimized oxygen and carbon dioxide exchange enhances physiological function.

    (iii) Conservation of Energy Law: Greater oxygen availability improves mechanical efficiency.

    Preliminary PX3™ testing has shown positive trends in airway efficiency, strength, balance, and endurance. In a study by Zupan et al. (2018), 25 participants demonstrated significantly faster 1.5-mile run times, greater anaerobic endurance, and higher leg-press strength when using the PX3™ device compared with a standard mouthguard or no mouthpiece. Nevertheless, the effects of this intervention on sleep quality and heart rate variability (HRV) - markers of recovery and autonomic balance - have not been evaluated in a controlled research setting.

  2. Research Question \& Objectives:

    Research Question: Does the PX3™ Mandibular Oral Repositioning Appliance improve sleep quality, heart rate variability, and blood oxygen saturation (SpO2) in healthy adults?

    Objectives:

    (i) To determine whether wearing the PX3™ appliance during sleep changes sleep stage distribution (deep, light, REM, awake), HRV, and SpO2 compared with a placebo device.

    (ii) To evaluate participant experience, comfort, and adherence.

  3. Methods:

Study Design:

A randomized crossover design will compare the effects of the PX3™ device versus a placebo oral appliance. Each participant will complete baseline, intervention, washout, and crossover phases over an 12-week period.

Participants:

An a priori power analysis (G*Power) indicated that 19 participants are needed to detect a large effect (Cohen's d = 0.80, α = 0.05, power = 0.90). To allow for some expected attrition (\~20%), 24 participants will be recruited.

Inclusion criteria:

  • Age 40-65 years, BMI 25-35 kg/m²
  • Full permanent dentition to first molar
  • No diagnosed underbite, braces, dentures, or planned dental work
  • Not currently using a CPAP device

Procedures:

Participants meeting inclusion criteria will undergo digital oral scans (upper, lower, and occlusal) to fabricate two custom devices. All scans will be completed at Tuscany Dental Centre (11300 Tuscany Blvd NW, Suite 2078, Calgary, AB T3L 2V7) and will be performed or overseen by Dr. Cam Brauer, a licensed dentist. The iTero digital oral scanner is a non-invasive, radiation-free optical imaging device used to obtain high-resolution 3D models of a participant's teeth and oral structures. The procedure involves using a handheld scanning wand to capture sequential images of the upper and lower arches and a brief bite registration. The wand does not contact any tissues, and the scan typically takes 8-12 minutes. This procedure is widely used in clinical practice and carries minimal risk. Potential minor discomforts may include mild jaw fatigue or a brief gag reflex, but no anesthetic or radiation is involved. All scan data are securely stored, de-identified, and transmitted in accordance with the study's data-management plan and relevant privacy regulations. Scans are performed by trained dental professionals following standard infection-control procedures.

The Placebo Device (PD) is a splint in centric occlusion with no mandibular advancement. The PX3™ Device advances the mandible 50-70% of maximum protrusion to improve alignment.

Each participant will receive a wrist-worn Garmin Forerunner 245 wearable device to continuously record sleep, HRV, and SpO2, except during bathing or charging. The device will be paired to the participant's smartphone using a study-specific Garmin Connect account created by the research team that does not contain personally identifying information. Data will be synced to the smartphone and retrieved by the research team on a rolling basis. Although the device is capable of collecting GPS data, GPS information will not be accessed, downloaded, or analyzed. Only sleep, HRV, and SpO2 metrics will be retained for research purposes. Data collection will occur over an 12-week period consisting of several phases: a 4-week baseline phase during which participants wear the monitor without any oral device; Phase 1 (3 weeks), where participants are randomized to either the PX3™ or placebo device; a 1-week washout period with no device use; Phase 2 (3 weeks), during which participants switch to the alternate device; and finally, a 1-week follow-up period of continued monitoring after completing both conditions.

Participants will wear the assigned oral appliance during sleep (mandatory) and may optionally use it during daytime. At each in-person visit, they will return devices and complete a survey on comfort, adherence, and perceived effects.

Participants will also maintain a nightly sleep log documenting their subjective sleep quality and any atypical factors that could influence restfulness (e.g., alcohol consumption, excessive exercise, illness, or travel). These notes will help contextualize variations in wearable-derived sleep and recovery metrics.

Data Analysis:

Sleep stage proportions (deep, light, REM, awake), HRV, and SpO2 data will be extracted from the wearable device for baseline and intervention phases. The percentage change in each variable will be calculated as:

% Change = [(Intervention - Baseline) / Baseline] × 100%

Paired t-tests will compare mean percentage changes between PX3™ and placebo conditions for sleep, HRV, and SpO2 outcomes. Statistical significance will be set at α = 0.05.

03

Conditions studied

  • Sleep

Keywords

  • mandibular oral appliance
  • sleep quality
  • heart rate variability
  • oxygen saturation
  • airway patency
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged 40-65 years
  • Male or female
  • (BMI) between 25 and 35 kg/m²
  • Full set of permanent teeth to the first molar
  • No clinically diagnosed underbite (Class III malocclusion)
  • Generally healthy with no diagnosed sleep disorders
  • Not currently using continuous positive airway pressure (CPAP) therapy
  • Employed in predominantly desk-based or professional roles

Exclusion criteria

Exclusion Criteria:

  • Diagnosed underbite (Class III malocclusion)
  • Current orthodontic treatment, braces, dentures, or pending dental work
  • Use of CPAP therapy or diagnosis of severe sleep apnea
  • Significant temporomandibular joint (TMJ) pain or dysfunction
  • Current smoker or use of tobacco or vaping products
  • Presence of major medical or psychiatric conditions that may affect sleep or autonomic function (e.g., cardiovascular disease, uncontrolled hypertension, anxiety, or depression)
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    px3

    The PX3™ Mandibular Oral Repositioning Appliance is designed to advance and stabilize the lower jaw, optimizing airway openness and physiological efficiency. The device functions similarly to the airway-opening maneuver used in cardiopulmonary resuscitation, slightly bringing the mandible forward to facilitate airflow. Each PX3™ appliance is custom-fitted to align and lock opposing teeth, stabilizing the jaw during sleep or high-stress activities. PX3™ designs are based on three physical principles: (i) Poiseuille's Law: Increasing airway volume increases oxygen intake. (ii) Gas Exchange Law: Optimized oxygen and carbon dioxide exchange enhances physiological function. (iii) Conservation of Energy Law: Greater oxygen availability improves mechanical efficiency.

    Device: Mandibular Oral Repositioning Appliance

  • Placebo comparator
    Placebo Device

    The Placebo Device is a splint in centric occlusion with no mandibular advancement. The PX3™ Device advances the mandible 50-70% of maximum protrusion to improve alignment.

    Device: Mandibular Oral Repositioning Appliance

Interventions

  • DeviceMandibular Oral Repositioning Appliance

    The PX3™ Mandibular Oral Repositioning Appliance is designed to advance and stabilize the lower jaw, optimizing airway openness and physiological efficiency. The device functions similarly to the airway-opening maneuver used in cardiopulmonary resuscitation, slightly bringing the mandible forward to facilitate airflow. Each PX3™ appliance is custom-fitted to align and lock opposing teeth, stabilizing the jaw during sleep or high-stress activities. PX3™ designs are based on three physical principles: (i) Poiseuille's Law: Increasing airway volume increases oxygen intake. (ii) Gas Exchange Law: Optimized oxygen and carbon dioxide exchange enhances physiological function. (iii) Conservation of Energy Law: Greater oxygen availability improves mechanical efficiency.

06

What researchers measure

Primary outcomes

  1. Total Sleep Duration

    Total sleep duration will be measured using a wrist-worn Garmin Forerunner 245 wearable device. Sleep duration will be calculated as the total time classified as sleep during each recorded night across baseline and intervention phases. Unit of Measure: Minutes (or hours)

    Time frame: Baseline (no oral appliance) and throughout each intervention phase while wearing the PX3™ device and the placebo device, through study completion (up to approximately 12 weeks)

  2. Sleep Stage Proportions

    Sleep stage proportions (deep sleep, light sleep, REM sleep, and awake time) will be measured using a wrist-worn Garmin Forerunner 245 wearable device. Sleep stage data will be recorded continuously during baseline and intervention phases and summarized as the proportion of total sleep time spent in each sleep stage. Unit of Measure: Percentage (%) of total sleep time

    Time frame: Baseline (no oral appliance) and throughout each intervention phase while wearing the PX3™ device and the placebo device, through study completion (up to approximately 12 weeks)

  3. Heart Rate Variability (HRV)

    Heart rate variability will be measured using a wrist-worn Garmin Forerunner 245 wearable device. HRV data will be collected continuously during baseline and intervention phases and extracted for analysis using device-derived metrics. Unit of Measure: Milliseconds (ms)

    Time frame: Baseline (no oral appliance) and throughout each intervention phase while wearing the PX3™ device and the placebo device, through study completion (up to approximately 12 weeks)

  4. Blood Oxygen Saturation (SpO2)

    Blood oxygen saturation (SpO₂) will be measured using a wrist-worn Garmin Forerunner 245 wearable device. SpO₂ data will be recorded during sleep periods throughout baseline and intervention phases and extracted for analysis. Unit of Measure: Percentage (%)

    Time frame: Baseline (no oral appliance) and throughout each intervention phase while wearing the PX3™ device and the placebo device, through study completion (up to approximately 12 weeks)

Secondary outcomes

  1. Participant Comfort With the Device

    Participant-reported comfort while wearing the device will be assessed using a survey administered after each study condition. Unit of Measure: Likert scale (as defined in the survey)

    Time frame: Baseline (no oral appliance) and throughout each intervention phase while wearing the PX3™ device and the placebo device, through study completion (up to approximately 12 weeks)

  2. Participant Adherence to Device Use

    Participant adherence to wearing the device as instructed will be assessed using a self-reported survey administered after each study condition. Unit of Measure: Likert scale or percentage of prescribed wear time (as defined in the survey)

    Time frame: Immediately after each intervention phase (after Condition 1 and after Condition 2)

  3. Participant Experience Using the Device

    Overall participant experience using the device will be assessed using a survey administered after each study condition. Unit of Measure: Likert scale (as defined in the survey)

    Time frame: Immediately after each intervention phase (after Condition 1 and after Condition 2)

  4. Participant-Perceived Effects of the Device

    Participant-perceived effects of the device on sleep, recovery, or daily functioning will be assessed using a survey administered after each study condition. Unit of Measure: Likert scale (as defined in the survey)

    Time frame: Immediately after each intervention phase (after Condition 1 and after Condition 2)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared. Data collected in this study include detailed physiological and health-related measures, and sharing individual-level data could increase the risk of participant re-identification. Only aggregated, de-identified summary results will be reported and shared in publications or presentations, in accordance with institutional ethics approval and data-governance policies.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Aug 2026, 6 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 6 months is below that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Jan 22, 2026
StartActual
Feb 11, 2026
Primary completionEst.
Aug 31, 2026
CompletionEst.
Oct 31, 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07359638
Collaborators
Canadian Sport Institute Alberta, PX3
Responsible party
Christian Clermont (Adjunct Assistant Professor, University of Calgary) — Principal investigator
First posted
Jan 22, 2026
Start date
Feb 11, 2026
Primary completion
Aug 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
May 1, 2026

Study contacts

Christian A Clermont, PhD
Contact
christian.clermont@ucalgary.ca
306-530-4787
Christian A Clermont, PhD
principal investigator · University of Calgary

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion